Novartis AG ADR (NVS)vsSol Gel Technologies Ltd (SLGL)
NVS
Novartis AG ADR
$148.18
-1.02%
HEALTHCARE · Cap: $286.44B
SLGL
Sol Gel Technologies Ltd
$68.54
-13.46%
HEALTHCARE · Cap: $99.10M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 236723% more annual revenue ($56.67B vs $23.93M). NVS leads profitability with a 24.7% profit margin vs -14.2%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
SLGL
Hold40
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-243.2%
Fair Value
$48.69
Current Price
$148.18
$99.49 premium
Intrinsic value data unavailable for SLGL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 27.8%
Generating 1.6B in free cash flow
Strong operational efficiency at 65.1%
Revenue surging 217.7% year-over-year
Earnings expanding 487.6% YoY
Areas to Watch
2.2% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Earnings declined 11.6%
Smaller company, higher risk/reward
ROE of -10.2% — below average capital efficiency
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.
Bull Case : SLGL
The strongest argument for SLGL centers on Operating Margin, Revenue Growth, EPS Growth. Revenue growth of 217.7% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.
Bear Case : SLGL
The primary concerns for SLGL are Market Cap, Return on Equity, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a value stock while SLGL is a hypergrowth play — different risk/reward profiles.
SLGL carries more volatility with a beta of 1.38 — expect wider price swings.
SLGL is growing revenue faster at 217.7% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 40/100), backed by strong 24.7% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Sol Gel Technologies Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Sol-Gel Technologies Ltd., a specialty clinical-stage pharmaceutical company, is focused on developing and commercializing topical dermatological pharmaceuticals based on its Israel-patented microencapsulation delivery system. The company is headquartered in Ness Ziona, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?